Repair Biotechnologies, Inc.

Syracuse, NY · Founded 2018 · CIK 0001750699 · Biotech · Private

Cholesterol Degrading Platform (CDP) therapy enabling human cells to degrade cholesterol

repairbiotechnologies.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$25M
8 Form D · Nov 2025
11 months since last filing
Contracts
—
No federal contracts on record
Patents
12
1 granted · 11 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$450,000
Private capital raisedForm D · SEC$75,000
Private capital raisedForm D · SEC$1,270,000
Private capital raisedForm D · SEC$2,855,000
Private capital raisedForm D · SEC$200,000
Private capital raisedForm D · SEC$8,389,479
Private capital raisedForm D · SEC$6,166,000
Private capital raisedForm D · SEC$5,258,906
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1616Generate Biomedicines——
1617Provizigen LLC——
1618ALZHEON, INC.—$134M
1619Repair Biotechnologies, Inc.—$25M
1620REELIN THERAPEUTICS, INC.——
1621DASFANH BIOSCIENCES, LLC——
1622Verdiva Bio——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 6 related persons
  • Guilherme Cherman Perdigao de OliveiraDirector · Executive Officer
  • Guilherme Cherman Perdig?o de OliveiraDirector
  • Anthony ChowDirector
  • Kelsey MoodyDirector
  • Reason N/ADirector · Executive Officer
  • Guilherme OliveiraDirector

Patents

USPTO · 1 granted of 12
  • Targeted Expression Of Microbial Cholesterol Catalysis Genes Reduces Excess Lipidgranted
  • Hepatocellular Carcinoma Treatments, Prophylactic Therapies, And Compositions For Use Therewithapplication
  • Enhancing Mitochondrial-based Flow And Catabolism Of Cholesterolapplication
  • Enhancing Mitochondrial-based Flow And Catabolism Of Cholesterolapplication
  • Targeted Expression Of Microbial Cholesterol Catalysis Genes Reduces Excess Lipidapplication
  • Hepatocellular Carcinoma Treatments, Prophylactic Therapies, And Compositions For Use Therewithapplication
  • Enhancing Mitochondrial-based Flow And Catabolism Of Cholesterolapplication
  • Targeted Expression Of Microbial Cholesterol Catalysis Genes Reduces Excess Lipidapplication
  • Atherosclerotic Plaque Reduction Treatments And Compositionsapplication
  • Targetted Expression Of Microbial Cholesterol Catalysis Genes Reduces Excess Lipid In Liverapplication
  • Atherosclerotic Plaque Reduction Treatments And Compositionsapplication
  • Hepatocellular Carcinoma Treatments, Prophylactic Therapies And Compositions For Use Therewithapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.